NEWS

ResMed gains but supply squeeze bites ability to grow

MELBOURNE: ResMed boss Mick Farrell is tipping as much as $US350 million ($470 ... read more

ResMed result is no dream for investors say analysts

MELBOURNE: ResMed shares have fallen by as much as 3.3 per cent throughout ... read more

Ownership Matters adds up Mesoblast cash outflows

MELBOURNE: Get the marshmallows ready, the bonfireā€™s set to hit $1 billion at ... read more

Wesfarmers seeks more info from API on financial position

PERTH: Wesfarmers is believed to be lobbying Priceline owner Australian Pharmaceutical Industries for ... read more